Stock & Company Details
Kiniksa Pharmaceuticals Ltd $KNSA
Price:
N/A
N/A
48M
$6.1B
52 Week High:
N/A
10 Day Average Volume:
N/A
80.13
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
KNSA technical indicators
Latest Kiniksa Pharmaceuticals Ltd (KNSA) indicator readings as of 2026-10-09.
KNSA's 14-day RSI is 61.3, in neutral territory. At $79.78 it is trading 39.7% above its 200-day moving average of $57.11, and above its 50-day average of $77.50. Price sits above the upper Bollinger Band ($73.86 to $79.73). ADX reads 16.3, indicating a range-bound market rather than a trend.
KNSA backtested strategy results
How 4 rule-based strategies performed on Kiniksa Pharmaceuticals Ltd (KNSA) over recent history, last backtested 2026-09-12. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +67.5% | 60% | 5 | -24.4% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -47.8% | 34% | 29 | -69.7% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -24.0% | 39% | 31 | -38.4% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +20.2% | 59% | 17 | -36.5% |
Overview
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.
Finance Bot
Ask your questions
Start by typing a question below.
